RU2008152776A - СОЕДИНЕНИЯ ЗАМЕЩЕННОГО ПИРАЗОЛО[1,5-a]ПИРИДИНА И СПОСОБЫ ИХ ПРИМЕНЕНИЯ - Google Patents

СОЕДИНЕНИЯ ЗАМЕЩЕННОГО ПИРАЗОЛО[1,5-a]ПИРИДИНА И СПОСОБЫ ИХ ПРИМЕНЕНИЯ Download PDF

Info

Publication number
RU2008152776A
RU2008152776A RU2008152776/04A RU2008152776A RU2008152776A RU 2008152776 A RU2008152776 A RU 2008152776A RU 2008152776/04 A RU2008152776/04 A RU 2008152776/04A RU 2008152776 A RU2008152776 A RU 2008152776A RU 2008152776 A RU2008152776 A RU 2008152776A
Authority
RU
Russia
Prior art keywords
substituted
compound
pyridine
pyrazolo
compound according
Prior art date
Application number
RU2008152776/04A
Other languages
English (en)
Russian (ru)
Inventor
Федерико К. А. ГАЭТА (US)
Федерико К. А. ГАЭТА
Мэттью ГРОСС (US)
Мэттью ГРОСС
Кирк В. ДЖОНСОН (US)
Кирк В. Джонсон
Original Assignee
Эвиджен Инк. (Us)
Эвиджен Инк.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Эвиджен Инк. (Us), Эвиджен Инк. filed Critical Эвиджен Инк. (Us)
Publication of RU2008152776A publication Critical patent/RU2008152776A/ru

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A61P25/36—Opioid-abuse
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Pain & Pain Management (AREA)
  • Addiction (AREA)
  • Pulmonology (AREA)
  • Psychiatry (AREA)
  • Rheumatology (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
RU2008152776/04A 2006-06-06 2007-06-06 СОЕДИНЕНИЯ ЗАМЕЩЕННОГО ПИРАЗОЛО[1,5-a]ПИРИДИНА И СПОСОБЫ ИХ ПРИМЕНЕНИЯ RU2008152776A (ru)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US81160406P 2006-06-06 2006-06-06
US60/811,604 2006-06-06

Publications (1)

Publication Number Publication Date
RU2008152776A true RU2008152776A (ru) 2010-07-20

Family

ID=38626513

Family Applications (1)

Application Number Title Priority Date Filing Date
RU2008152776/04A RU2008152776A (ru) 2006-06-06 2007-06-06 СОЕДИНЕНИЯ ЗАМЕЩЕННОГО ПИРАЗОЛО[1,5-a]ПИРИДИНА И СПОСОБЫ ИХ ПРИМЕНЕНИЯ

Country Status (9)

Country Link
US (3) US7585875B2 (fr)
EP (1) EP2038279A2 (fr)
JP (2) JP5352452B2 (fr)
AU (1) AU2007258567B2 (fr)
BR (1) BRPI0712381A2 (fr)
CA (1) CA2654498A1 (fr)
MX (1) MX2008015616A (fr)
RU (1) RU2008152776A (fr)
WO (1) WO2007146087A2 (fr)

Families Citing this family (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP5352452B2 (ja) * 2006-06-06 2013-11-27 メディシノバ， インコーポレイテッド 置換ピラゾロ［１，５−ａ］ピリジン化合物およびその使用方法
US20080181876A1 (en) * 2007-01-30 2008-07-31 Johnson Kirk W Methods for treating acute and subchronic pain
AR074870A1 (es) * 2008-12-24 2011-02-16 Palau Pharma Sa Derivados de pirazolo (1,5-a ) piridina
RU2011151603A (ru) * 2009-05-19 2013-06-27 ДАУ АГРОСАЙЕНСИЗ ЭлЭсСи Соединения и способы борьбы с грибами
TW201102387A (en) * 2009-06-08 2011-01-16 Medicinova Inc Substituted pyrazolo[1,5-a]pyridine compounds having multi-target activity
EP2445504A4 (fr) * 2009-06-23 2012-11-14 Medicinova Inc Compositions énantiomères de 2-amino-1-(2-isopropylpyrazolo[1,5-a]pyridine-3-yl)propane-1-one et procédés correspondants
UY33213A (es) * 2010-02-18 2011-09-30 Almirall Sa Derivados de pirazol como inhibidores de jak
EP2360158A1 (fr) * 2010-02-18 2011-08-24 Almirall, S.A. Dérivés de pyrazole en tant qu'inhibiteurs de JAK
EP2463289A1 (fr) 2010-11-26 2012-06-13 Almirall, S.A. Dérivés imidazo[1,2-b]pyridazine en tant qu'inhibiteur JAK
CA2822357A1 (fr) 2010-12-22 2012-06-28 Abbvie Inc. Inhibiteurs de l'hepatite c et leurs utilisations
EP2701700A4 (fr) * 2011-04-27 2015-10-21 Univ Yale Inc Pharmacothérapie pour empêcher des effets indésirables induits par une chimiothérapie et compositions pharmaceutiques, diagnostics, techniques de dépistage et trousses associés
EP2554544A1 (fr) 2011-08-01 2013-02-06 Almirall, S.A. Dérivés de pyridin-2(1h)-one en tant qu'inhibiteurs de JAK
CN102617579A (zh) * 2012-03-28 2012-08-01 黑龙江大学 一种异丁司特的制备方法
US8871754B2 (en) 2012-11-19 2014-10-28 Irm Llc Compounds and compositions for the treatment of parasitic diseases
CN105164124B (zh) 2012-11-19 2017-03-15 诺华股份有限公司 用于治疗寄生虫疾病的化合物和组合物
JP2023541464A (ja) * 2020-09-15 2023-10-02 ファースト・バイオセラピューティクス・インコーポレイテッド ２－アミノ－３－カルボニルイミダゾピリジン及びピラゾロピリジン化合物
CN117479933A (zh) * 2020-12-18 2024-01-30 佛罗里达大学研究基金会公司 用于治疗神经退行性病症、退行性病症和代谢病症的化合物及其用途
WO2023122756A2 (fr) * 2021-12-22 2023-06-29 Board Of Trustees Of Michigan State University Inhibiteurs ulk1 et ulk2
CN115716828A (zh) * 2022-11-04 2023-02-28 华南理工大学 一种吡唑并[1,5-a]吡啶类化合物的合成方法

Family Cites Families (31)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS5229318B2 (fr) * 1972-03-30 1977-08-01
JPS5154583A (en) * 1974-11-01 1976-05-13 Kyorin Seiyaku Kk Shinkipirazoro * 1 55a * pirijinjudotaino seizoho
US4097483A (en) * 1974-11-01 1978-06-27 Kyorin Pharmaceutical Co., Ltd. Pyrazolo 1,5-a!pyridines
JPS59167590A (ja) * 1983-03-14 1984-09-21 Kyorin Pharmaceut Co Ltd ピラゾロ〔１，５−ａ〕ピリジン誘導体、その製法及びそれを含有する治療剤
JPS59175491A (ja) * 1983-03-26 1984-10-04 Kyorin Pharmaceut Co Ltd ピラゾロピリジン誘導体、その製法及びそれを含有する治療剤
JPH0621066B2 (ja) * 1984-03-14 1994-03-23 杏林製薬株式会社 ３―イソブチリル―２―イソプロピルピラゾロ〔１，５―ａ〕ピリジンの徐放性医薬品組成物
US4925849A (en) * 1987-06-15 1990-05-15 Fujisawa Pharmaceutical Company, Ltd. Pharmaceutically useful pyrazolopyridines
GB8901423D0 (en) * 1989-01-23 1989-03-15 Fujisawa Pharmaceutical Co Pyrazolopyridine compound and processes for preparation thereof
GB9107513D0 (en) * 1991-04-10 1991-05-29 Fujisawa Pharmaceutical Co Pyrazolopyridine compound and processes for preparation thereof
FR2687675B1 (fr) * 1992-01-31 1997-04-18 Roussel Uclaf Nouveaux derives bicycliques de la pyridine, leur procede de preparation, les nouveaux intermediaires obtenus, leur application a titre de medicaments et les compositions pharmaceutiques les renfermant.
JPH07215974A (ja) * 1994-02-03 1995-08-15 Kyorin Pharmaceut Co Ltd アリールエテニルピラゾロピリジン誘導体及びその製造法
ATE229527T1 (de) * 1996-10-04 2002-12-15 Kyorin Seiyaku Kk Pyrazolopyridylpyrazinon-derivate und ein verfahren zu ihrer herstellung
DE69941100D1 (de) * 1998-05-27 2009-08-20 Genzyme Corp AAV Vektoren zur Herstellung der Medikamente zur konvektion-erhöhten Verabreichung
AUPP672198A0 (en) * 1998-10-23 1998-11-19 Fujisawa Pharmaceutical Co., Ltd. Pyrazolopyridine compound and pharmaceutical use thereof
CN1263755C (zh) * 1998-11-03 2006-07-12 葛兰素集团有限公司 作为选择性cox－2抑制剂的吡唑并吡啶衍生物
DE69915519T2 (de) * 1999-02-27 2005-02-03 Glaxo Group Ltd., Greenford Pyrazolopyridine
WO2001019321A2 (fr) * 1999-09-15 2001-03-22 Elan Pharmaceuticals, Inc. Procedes permettant de traiter la douleur nevropathique par les heteroarylmethanesulfamides
PE20020506A1 (es) * 2000-08-22 2002-07-09 Glaxo Group Ltd Derivados de pirazol fusionados como inhibidores de la proteina cinasa
AUPQ969800A0 (en) 2000-08-28 2000-09-21 Fujisawa Pharmaceutical Co., Ltd. Pyrazolopyridine compound and pharmaceutical use thereof
AUPR916301A0 (en) * 2001-11-29 2001-12-20 Fujisawa Pharmaceutical Co., Ltd. Pyrazolopyridine compound and pharmaceutical use thereof
WO2004024074A2 (fr) * 2002-09-13 2004-03-25 Merck & Co., Inc. Modulateurs du recepteur glutamate metabotropique 5 (mglur5) de phenyle substitues par un fragment heterobicyclo fusionne
GB0303910D0 (en) * 2003-02-20 2003-03-26 Merck Sharp & Dohme Therapeutic agents
US20050192261A1 (en) 2003-09-15 2005-09-01 Jost-Price Edward R. Methods and reagents for the treatment of immunoinflammatory disorders
CN1905870A (zh) 2003-11-21 2007-01-31 康宾纳特克斯公司 用于治疗炎性病症的方法和试剂
PE20060241A1 (es) * 2004-05-18 2006-04-01 Schering Corp 2-quinolil-oxazoles sustituidos como inhibidores de pde4
US7459451B2 (en) 2004-07-05 2008-12-02 Astellas Pharma Inc. Pyrazolopyridine derivatives
JP2006117647A (ja) * 2004-09-22 2006-05-11 Kyorin Pharmaceut Co Ltd ハロゲノピラゾロピリジンピリダジノン誘導体とその付加塩及びそれを有効成分とするｐｄｅ阻害剤
AU2005302523A1 (en) * 2004-10-28 2006-05-11 Celgene Corporation Methods and compositions using PDE4 modulators for treatment and management of central nervous system injury
DE102004057618A1 (de) * 2004-11-29 2006-06-01 Boehringer Ingelheim Pharma Gmbh & Co. Kg Substituierte Pteridine zur Behandlung von entzündlichen Erkrankungen
EP1835913A2 (fr) * 2004-12-06 2007-09-26 Avigen, Inc. Jbudilast pour le traitement de la douleur neuropathique et des syndromes associés
JP5352452B2 (ja) * 2006-06-06 2013-11-27 メディシノバ， インコーポレイテッド 置換ピラゾロ［１，５−ａ］ピリジン化合物およびその使用方法

Also Published As

Publication number Publication date
MX2008015616A (es) 2009-02-11
AU2007258567B2 (en) 2012-04-19
JP5352452B2 (ja) 2013-11-27
JP2013189479A (ja) 2013-09-26
JP2009539851A (ja) 2009-11-19
US20080070912A1 (en) 2008-03-20
CA2654498A1 (fr) 2007-12-21
WO2007146087A3 (fr) 2008-03-20
EP2038279A2 (fr) 2009-03-25
BRPI0712381A2 (pt) 2012-07-10
US20090318437A1 (en) 2009-12-24
US7585875B2 (en) 2009-09-08
AU2007258567A1 (en) 2007-12-21
US20100035920A1 (en) 2010-02-11
WO2007146087A2 (fr) 2007-12-21

Similar Documents

Publication Publication Date Title
RU2008152776A (ru) СОЕДИНЕНИЯ ЗАМЕЩЕННОГО ПИРАЗОЛО[1,5-a]ПИРИДИНА И СПОСОБЫ ИХ ПРИМЕНЕНИЯ
US8642602B2 (en) Method of inhibiting fibrogenesis and treating fibrotic disease
CA2493225A1 (fr) Derives de quinoleine et leur utilisation en tant qu'inhibiteurs mycobacteriens
RU2006137794A (ru) Химические составы, композиции и способы их использования
JP2009539851A5 (fr)
KR20080096570A (ko) 이미다졸계 화합물, 그를 포함하는 조성물 및 그의 사용 방법
RU2010139806A (ru) Новые производные пирроло[3,2-d]пиримидин-4-она и их применение в терапии
CA2569691A1 (fr) Methodes et compositions pour traitement de manifestations ophtalmiques au moyen de derives de retinyl
WO2010097334A1 (fr) Associations de médicaments contenant des inhibiteurs de pde4 et des ains
AU2005249231A1 (en) Use of substituted quinoline derivatives for the treatment of drug resistant mycobacterial diseases
JP2018507235A (ja) ステロール調節エレメント結合タンパク質（ｓｒｅｂｐ）阻害剤
RU2012110380A (ru) Новое производное 5-фторурацила
EP2609082A1 (fr) Imidazo[4,5-c]quinoléines utilisées comme inhibiteurs de l'adn-pk
RU2007148412A (ru) 6,7-ненасыщенное 7-карбамоилзамещенное производное морфинана
NO20076425L (no) Fremgangsmater for behandling av drug-resistent cancer
KR102634575B1 (ko) 지방세포의 처리
RU2007139928A (ru) Производное бензимидазола и применение в качестве антагониста ангиотензина
US20100222376A1 (en) Chelerythrine, analogs thereof and their use in the treatment of bipolar disorder and other cognitive disorders
DE60014916D1 (de) Die Verwendung eines Benzimidazoles zur Herstellung eines Medikamentes zur Krebsvorbeugung
CN109069461A (zh) 与髓源性抑制细胞相关的病症的治疗方法
RU2521286C2 (ru) Модуляторы рецептора сфингозин-1-фосфата (s1p) и их применение для лечения воспаления мышечной ткани
WO2006129168A3 (fr) Derives bicycliques pour le traitement de croissance cellulaire anormale
EA201100476A1 (ru) Агонист глюкокортикоидного рецептора, содержащий новые производные 1,2,3,4-тетрагидрохиноксалина с фенильной группой, имеющей структуру эфира сульфоновой кислоты, введенной в нее в качестве заместителя
JP2010518860A (ja) Ｌｙｎキナーゼの活性化剤の同定方法
BR0317433A (pt) Derivados bicìclicos para o tratamento do crescimento celular anormal

Legal Events

Date Code Title Description
FA92 Acknowledgement of application withdrawn (lack of supplementary materials submitted)

Effective date: 20111018